Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
$2.52
$1.61
$4.40
$45.72M2.2482,013 shs63,385 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.49
+0.4%
$2.06
$0.40
$3.10
$201.55M2.052.20 million shs755,783 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.82
-1.8%
$4.14
$2.55
$6.42
$193.48M1.0810,522 shs330 shs
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.42
+2.9%
$1.31
$0.85
$2.08
$191.53M1.36659,440 shs546,098 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00%0.00%0.00%0.00%-25.70%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
0.00%+10.67%+3.75%+446.53%+91.54%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.00%+5.82%-13.87%+13.69%-4.02%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.00%+5.19%+8.40%+49.38%-10.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.0629 of 5 stars
3.51.00.04.71.21.71.3
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
1.9889 of 5 stars
3.54.00.00.00.00.00.0
Organigram Global Inc. stock logo
OGI
Organigram Global
0.5281 of 5 stars
0.01.00.00.00.60.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
0.00
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33114.19% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$13.00240.31% Upside
Organigram Global Inc. stock logo
OGI
Organigram Global
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ALRN, CTMX, OGI, and GNFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/A$1.41 per shareN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$147.56M1.36$0.36 per share6.91($0.01) per share-249.00
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$67.00M2.85$0.07 per share55.33$1.50 per share2.55
Organigram Global Inc. stock logo
OGI
Organigram Global
$194.09M0.98N/AN/A$2.07 per share0.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.485.19N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1014.20N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)

Latest ALRN, CTMX, OGI, and GNFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
N/A
3.30
3.30
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90

Institutional Ownership

CompanyInstitutional Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
90.89%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%

Insider Ownership

CompanyInsider Ownership
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
5.10%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aileron Therapeutics, Inc. stock logo
ALRN
Aileron Therapeutics
921.67 million20.56 millionNot Optionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
Organigram Global Inc. stock logo
OGI
Organigram Global
860133.94 million133.82 millionOptionable

Recent News About These Companies

OGI Organigram Global Inc. - Seeking Alpha
Organigram Global Inc. (OGI.TO)
Organigram acquires Collective Project for C$6.2M

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aileron Therapeutics stock logo

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.49 +0.01 (+0.40%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.49 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.82 -0.07 (-1.80%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.42 +0.04 (+2.90%)
Closing price 07/3/2025 03:34 PM Eastern
Extended Trading
$1.43 +0.01 (+0.70%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.